Three controlled trials of weight loss with phenylpropanolamine.
A multisite double-blind study was designed to determine the effectiveness of a phenylpropanolamine-caffeine combination in achieving weight loss. Two-hundred and one obese adult patients were divided into three separate groups in which phenylpropanolamine/caffeine was compared with either placebo (6 weeks), mazindol (6 weeks), or diethylpropion (8 weeks). In these clinical trials, phenylpropanolamine/caffeine proved to be as effective as mazindol and diethylpropion and significantly more effective than placebo in achieving weight loss. Overall, phenylpropanolamine/caffeine had fewer side effects than mazindol and diethylpropion. Its use as an effective anorectic agent in the treatment of obesity is reviewed.
D000293:Adolescent; D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight; D002110:Caffeine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004053:Diethylpropion / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D006801:Humans; D008454:Mazindol / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects
D001067:Appetite Depressants; D004338:Drug Combinations; D010665:Phenylpropanolamine; D002110:Caffeine; D008454:Mazindol; D004053:Diethylpropion